Clinuvel Pharmaceuticals Limited

CUV

AU000000CUV3

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 02:10:46 2024-04-19 am EDT			5-day change	1st Jan Change
14.38 ^AUD	-5.95%		-4.77%	-10.12%

Mar. 14	Clinuvel Pharmaceuticals Launches Share Buyback Program	MT
Mar. 14	Morgans Financial Upgrades Clinuvel Pharmaceuticals to Add From Hold; Price Target is AU$16	MT

Clinuvel Pharmaceuticals Limited Announces Dividend for the Full Year Ended June 30, 2020, Payable on September 18, 2020

August 26, 2020 at 08:19 pm EDT

Clinuvel Pharmaceuticals Limited announced ordinary fully paid dividend of AUD 0.025 per share for the full year ended June 30, 2020. Ex-date is September 3, 2020. Record date is September 4, 2020. Payment date is September 18, 2020.

Latest news about Clinuvel Pharmaceuticals Limited

Clinuvel Pharmaceuticals Launches Share Buyback Program	Mar. 14	MT
Morgans Financial Upgrades Clinuvel Pharmaceuticals to Add From Hold; Price Target is AU$16	Mar. 13	MT
Clinuvel Pharmaceuticals Limited announces an Equity Buyback for 1,500,000 shares, representing 2.99% of its issued share capital.	Mar. 13	CI
Clinuvel Pharmaceuticals Limited authorizes a Buyback Plan.	Mar. 13	CI
Clinuvel Reports Positive Results in SCENESSE Study	Mar. 03	MT
Transcript : Clinuvel Pharmaceuticals Limited, H1 2024 Earnings Call, Feb 22, 2024	Feb. 22
Clinuvel Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 21	CI
Clinuvel Pharmaceuticals Limited Announces Change to Registered Office	Dec. 06	CI
Clinuvel Doses First Patient in Phase 3 Trial of Vitiligo Treatment	23-10-18	MT
Transcript : Clinuvel Pharmaceuticals Limited - Special Call	23-10-01
Clinuvel Pharmaceuticals Limited Announces Board Changes	23-09-28	CI
Clinuvel Pharmaceuticals Teams Up With Vitiligo Experts to Assess Scenesse	23-09-13	MT
Transcript : Clinuvel Pharmaceuticals Limited, 2023 Earnings Call, Aug 29, 2023	23-08-29
Clinuvel Pharmaceuticals Limited Announces Dividend for the Full Year Ended June 30, 2023, Payable on September 20, 2023	23-08-28	CI
Clinuvel Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-28	CI
Clinuvel Pharmaceuticals Secures Supply Contract for Porphyria Medication with the US Department of Veterans Affairs	23-07-26	MT
Clinuvel Pharmaceuticals Secures Patents for Melanocortins for Treatment of Central Nervous System Disorders	23-07-13	MT
Clinuvel Pharmaceuticals Treats First Patient in Phase Two Stroke Trial	23-03-20	MT
Clinuvel Pharmaceuticals Limited Announces Technical Note - CUV803 Study and AIS	23-03-19	CI
Clinuvel Pharmaceuticals Limited Announces First Stroke Patient Treated with PRENUMBRA Instant	23-03-19	CI
Clinuvel Pharmaceuticals Limited Present DNA Repair Data At American Academy of Dermatology Meeting	23-03-16	CI
Clinuvel Pharmaceuticals Says It Has No Deposits at Silicon Valley Bank	23-03-12	MT
Clinuvel Pharmaceuticals Launches Skin Protection Product	23-02-28	MT
Clinuvel Launches Cyacle, Next Generation Solar Care	23-02-28	CI
CLINUVEL Launches First Dermatocosmetic Product	23-02-28	CI

Chart Clinuvel Pharmaceuticals Limited

Duration

Period

More charts

Company Profile

Clinuvel Pharmaceuticals Limited is a global specialty pharmaceutical company. The Company is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. The Company is engaged in managing and expanding commercial distribution of its lead drug candidate, SCENESSE, in Europe, the United States, Israel, and Australia for the treatment of a rare, genetic metabolic disorder, erythropoietic protoporphyria (EPP). The Companyâs pipeline includes PRENUMBRA, NEURACTHEL, CUV9900, and Parvysmelanotide (VLRX001). PRENUMBRA is a liquid (non-solid) injectable formulation of afamelanotide designed to provide a flexible dose of afamelanotide, a synthetic analogue of natural a-melanocyte stimulating hormone. NEURACTHEL is a novel formulation of the melanocortin adrenocorticotropic hormone (ACTH), for neurological, endocrinological and degenerative disorders.

Sector

Pharmaceuticals

Calendar

2024-08-27 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Clinuvel Pharmaceuticals Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

15.29 AUD

Average target price

25.01 AUD

Spread / Average Target

+63.57%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
CLINUVEL PHARMACEUTICALS LIMITED	-10.12%	493M
CSL LIMITED	-5.99%	84.46B
SAMSUNG BIOLOGICS CO.,LTD.	+3.95%	40.85B
BIOGEN INC.	-26.37%	27.69B
UCB	+50.95%	24.28B
BIOMARIN PHARMACEUTICAL INC.	-6.59%	17.09B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-32.37%	13.67B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-10.45%	11.79B
INCYTE CORPORATION	-15.88%	11.86B
SWEDISH ORPHAN BIOVITRUM AB	-3.82%	8.07B

Biopharmaceuticals